Title |
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
|
---|---|
Published in |
Cancer Discovery, August 2014
|
DOI | 10.1158/2159-8290.cd-14-0341 |
Pubmed ID | |
Authors |
Arabella Young, Deepak Mittal, John Stagg, Mark J. Smyth |
Abstract |
CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases, and poor disease outcomes. Therapies targeted toward the adenosinergic pathway, such as antibodies targeting CD73 and CD39, have proven efficacy in mouse tumor models; however, humanized versions are only in preliminary development. In contrast, A2A adenosine receptor antagonists have progressed to late-stage clinical trials in Parkinson disease, yet evidence of their role in oncology is limited. This review will compare the merits and challenges of these therapeutic approaches, identifying tumor indications and combinations that may be fruitful as they progress to the clinic. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 2 | <1% |
Denmark | 1 | <1% |
Germany | 1 | <1% |
Italy | 1 | <1% |
Unknown | 269 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 70 | 26% |
Student > Ph. D. Student | 37 | 14% |
Student > Master | 29 | 11% |
Student > Bachelor | 20 | 7% |
Professor | 18 | 7% |
Other | 48 | 18% |
Unknown | 52 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 52 | 19% |
Medicine and Dentistry | 47 | 17% |
Biochemistry, Genetics and Molecular Biology | 38 | 14% |
Immunology and Microbiology | 31 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 17 | 6% |
Other | 27 | 10% |
Unknown | 62 | 23% |